Heterogeneity analysis of the CEBPAdm AML based on bZIP region mutations

Heterogeneity analysis of the CEBPAdm AML based on bZIP region mutations

In the evolving landscape of hematology, a recent study led by Professor Jianxiang Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, investigated the heterogeneity of double-mutated CEBPA (CEBPAdm) acute myeloid leukemia (AML). Analyzing 2211 newly diagnosed AML patients, the study found that 10.8% had CEBPAdm, with 94.14% exhibiting bZIP region mutations (CEBPAdmbZIP) and 5.86% without (CEBPAdmnonbZIP). The research revealed significant differences in GATA2 mutation incidence (30.29% in CEBPAdmbZIP vs. 0% in CEBPAdmnonbZIP) and shorter overall survival for patients with CEBPAdmnonbZIP. These findings highlight the necessity of considering CEBPAdm with and without bZIP mutations as distinct entities, guiding more precise treatment approaches.
Immune Checkpoint Expression Patterns on T Cell Subsets in Light-Chain Amyloidosis: VISTA, PD-1, and TIGIT as Potential Therapeutic Targets

Immune Checkpoint Expression Patterns on T Cell Subsets in Light-Chain Amyloidosis: VISTA, PD-1, and TIGIT as Potential Therapeutic Targets

In the dynamic field of hematology and oncology, innovative treatments for systemic amyloid light chain (AL) amyloidosis are essential. Recent research, led by Professor Yangqiu Li from the Institute of Hematology, School of Medicine, Jinan University, explores immune checkpoint expression patterns in AL amyloidosis. This study investigates VISTA+, PD-1+, Tim-3+, and TIGIT+ T cells in newly diagnosed patients, highlighting the immunosuppressive environment of the disease. The findings reveal the potential of targeting VISTA, PD-1, and TIGIT to reverse T-cell exhaustion, offering new therapeutic avenues.
Optimizing Antibiotic Dosage in Obese and Underweight Patients: Insights from Professor Wenxiang Huang ‘s Presentation at ESCMID Global 2024

Optimizing Antibiotic Dosage in Obese and Underweight Patients: Insights from Professor Wenxiang Huang ‘s Presentation at ESCMID Global 2024

From April 27th to 30th, 2024, the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024) took place in Barcelona, Spain, known as the "Pearl of the Iberian Peninsula." ESCMID Global, formerly known as ECCMID, stands as one of the most influential international conferences in the field of infectious diseases. Often, clinical trials of antibiotics exclude special populations such as obese or underweight individuals, resulting in limited evidence for their treatment strategies. At this conference, several studies and advancements regarding antibiotic management and prescription, including interventions, monitoring, influences, decision support/predictive tools, and behavioral aspects, were reported. Below is a summary of the insights shared by Professor Wenxiang Huang  from the Department of Geriatrics at The First Affiliated Hospital of Chongqing Medical University.
Professor Hongfei Duan：Advances in Diagnosis and Treatment of Mycobacterium avium Complex (MAC) Pulmonary Disease

Professor Hongfei Duan：Advances in Diagnosis and Treatment of Mycobacterium avium Complex (MAC) Pulmonary Disease

Non-tuberculous mycobacteria (NTM) refers to all mycobacteria other than Mycobacterium tuberculosis and Mycobacterium leprae. NTM most commonly affect the lungs, causing NTM pulmonary disease (NTM-PD), which can even lead to disseminated disease in immunocompromised individuals. In recent years, with changes in the environment, updates in detection technology, and increased awareness among physicians, the incidence of NTM-PD has been steadily increasing, with Mycobacterium avium complex (MAC) pulmonary disease being the most common worldwide. At the recent Fourth National Conference of the Chinese Medical Association on Bacterial and Fungal Infections (BISC 2024), Professor Hongfei Duan from the Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, delivered a fascinating presentation titled "Advances in Diagnosis and Treatment of Mycobacterium avium Complex Pulmonary Disease," elucidating and analyzing the current status, challenges, and progress in the diagnosis and treatment of MAC pulmonary disease.
Professor Jingtao Li: Advances in Clinical Research on Traditional Chinese Medicine in the Prevention and Treatment of Liver Fibrosis

Professor Jingtao Li: Advances in Clinical Research on Traditional Chinese Medicine in the Prevention and Treatment of Liver Fibrosis

Liver fibrosis is the result of damage to the liver by pathogenic factors, leading to chronic, repeated abnormalities in liver function and the deposition of collagen and other proteins. It is a crucial factor influencing the prognosis of chronic liver disease and a necessary stage in the progression to cirrhosis. Recently, at the 25th National Conference on Traditional Chinese Medicine and Hepatobiliary Diseases organized by the Chinese Association of Traditional Chinese Medicine, Professor Jingtao Li from the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine presented the latest clinical research advancements in the prevention and treatment of liver fibrosis using Traditional Chinese Medicine (TCM). The multi-component, multi-target therapeutic features of TCM, along with the significant efficacy of several representative drugs, provide strong scientific support for the application of TCM in combating liver fibrosis.
Professor Ailong Huang: Mechanisms of Persistent HBV Infection

Professor Ailong Huang: Mechanisms of Persistent HBV Infection

Hepatitis B virus (HBV), a hepatotropic DNA virus, is the causative agent of hepatitis B. HBV-infected individuals have three types of particles in their blood: Dane particles, spherical particles, and tubular particles. The characteristics of these particles can be used to detect evidence of HBV infection through immunological methods. Recently, at the 17th National Conference on Clinical Hepatology, Professor Ailong Huang, President of Chongqing Medical University, delivered a report titled "Mechanisms of Persistent HBV Infection." This report provides an in-depth analysis of the mechanisms behind persistent HBV infection, revealing the relationship between abnormal host immune responses and viral evasion of host antiviral effects, offering new perspectives for understanding HBV persistence and developing treatment strategies.
EHA Expert Interview | Professor Jimin Shi: Better Pre-Transplant Treatment Options for TP53-Mutated MDS Patients: Cytoreductive or Non-Cytoreductive

EHA Expert Interview | Professor Jimin Shi: Better Pre-Transplant Treatment Options for TP53-Mutated MDS Patients: Cytoreductive or Non-Cytoreductive

Patients with TP53-mutated myelodysplastic syndromes (MDS) generally have poor prognoses and face significant treatment challenges. To improve the survival outcomes of these patients, Professor Jimin Shi's team at The First Affiliated Hospital, Zhejiang University School of Medicine conducted an in-depth investigation into the treatment options for TP53-mutated MDS patients before transplantation. At the recent 29th European Hematology Association (EHA) Annual Meeting, they presented the results of their study (P1367), which compared cytoreductive and non-cytoreductive therapies. To provide a comprehensive understanding of the findings and their implications, "Oncology Frontier - Hematology Frontier" invited Professor Jimin Shi to share insights from this research
EHA in 5 Minutes | Professor Linhua Yang: Latest Advances in Immune Thrombocytopenia Research (Part 1)

EHA in 5 Minutes | Professor Linhua Yang: Latest Advances in Immune Thrombocytopenia Research (Part 1)

Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by a low platelet count. At the recently held 29th European Hematology Association (EHA) Annual Meeting, significant advancements were made in the field of ITP. "Oncology Frontier - Hematology Frontier" invited Professor Linhua Yang from the Second Hospital of Shanxi Medical University to select and detail some of the most impactful studies. This issue presents two studies: one on clonal hematopoiesis in ITP and its clinical significance, and the other on the safety and efficacy of avatrombopag for treating chronic ITP in children, with the aim of deepening understanding of ITP and providing new insights for future treatment strategies.